Rheumatology
Partner With Us
Advertisement
Conexiant chevron_right Rheumatology chevron_right GLP1 Use Reduces Opioid Pain Fatigue Burdenin Fibromyalgia
Conference News EULAR 2025 - Congress

GLP-1 Use Associated with Less Pain, Fatigue

At the EULAR 2025 Congress, researchers reported that GLP-1 receptor agonists were linked to reduced opioid use, pain, and fatigue in fibromyalgia patients based on a large real-world analysis.

Conexiant
Full Article Summary Notecard
  1. Real-world evidence from the 2025 EULAR Congress indicates potential benefits of GLP-1 receptor agonists in reducing symptom burden for patients with fibromyalgia.
  2. The analysis used data from the TriNetX research network to compare large patient cohorts over a 5-year follow-up period.
  3. GLP-1 receptor agonists showed potential in reducing opioid use, chronic pain, fatigue, and ongoing fibromyalgia care.
  4. The observational design limits causal conclusions, highlighting the need for further evaluation through randomized controlled trials. 

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.